{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:38:13Z","timestamp":1793450293827,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"\n Importance<\/jats:title>\n Psilocybin shows promise as a treatment for major depressive disorder (MDD).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a\n Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition<\/jats:italic>\n diagnosis of MDD of at least 60 days\u2019 duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents who otherwise met inclusion\/exclusion criteria were eligible following medication taper. Primary and secondary outcomes and adverse events (AEs) were assessed at baseline (conducted within 7 days before dosing) and at 2, 8, 15, 29, and 43 days after dosing.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Interventions were a 25-mg dose of synthetic psilocybin or a 100-mg dose of niacin in identical-appearing capsules, each administered with psychological support.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was change in central rater\u2013assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43. The key secondary outcome measure was change in MADRS score from baseline to day 8. Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 and MADRS-defined sustained response and remission. Participants, study site personnel, study sponsor, outcome assessors (raters), and statisticians were blinded to treatment assignment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 104 participants (mean [SD] age, 41.1 [11.3] years; 52 [50%] women) were randomized (51 to the psilocybin group and 53 to the niacin group). Psilocybin treatment was associated with significantly reduced MADRS scores compared with niacin from baseline to day 43 (mean difference,\u221212.3 [95% CI, \u221217.5 to \u22127.2];\n P<\/jats:italic>\n &amp;lt;.001) and from baseline to day 8 (mean difference, \u221212.0 [95% CI, \u221216.6 to \u22127.4];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, \u22122.31 [95% CI, \u22123.50 to \u22121.11];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) from baseline to day 43. More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin. There were no serious treatment-emergent AEs; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin\u2014when administered with psychological support\u2014may hold promise as a novel intervention for MDD.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03866174<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.14530","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:57:22Z","timestamp":1693483042000},"page":"843","source":"Crossref","is-referenced-by-count":571,"title":["Single-Dose Psilocybin Treatment for Major Depressive Disorder"],"prefix":"10.1001","volume":"330","author":[{"given":"Charles L.","family":"Raison","sequence":"first","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Woolley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Pacific Neuroscience Institute, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boadie W.","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall T.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Family Medicine & Community Health, University of Wisconsin School of Medicine & Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Kakar","sequence":"additional","affiliation":[{"name":"Center for Psychedelic Research, Segal Trials, Lauderhill, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hassman","sequence":"additional","affiliation":[{"name":"Hassman Research Institute, Berlin, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal P.","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Flourish Research, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Robison","sequence":"additional","affiliation":[{"name":"Numinus Wellness, Draper, Utah"},{"name":"Department of Psychiatry, University of Utah School of Medicine, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gukasyan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep M.","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojue","family":"Hu","sequence":"additional","affiliation":[{"name":"NYU Langone Center for Psychedelic Medicine, Department of Psychiatry, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley C.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"NYU Langone Center for Psychedelic Medicine, Department of Psychiatry, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kelmendi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Sloshower","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Penn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California San Francisco"},{"name":"School of Nursing, University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of California San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Pacific Neuroscience Institute, Santa Monica, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Mletzko","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Department of Family Medicine & Community Health, University of Wisconsin School of Medicine & Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Hutson","sequence":"additional","affiliation":[{"name":"Pharmacy Practice & Translational Research Division, School of Pharmacy, University of Wisconsin-Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Tarpley","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malynn","family":"Utzinger","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Lenoch","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Warchol","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theraysa","family":"Gapasin","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike C.","family":"Davis","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Nelson-Douthit","sequence":"additional","affiliation":[{"name":"The Emmes Company, Inc, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffanie","family":"Wilson","sequence":"additional","affiliation":[{"name":"The Emmes Company, Inc, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Brown","sequence":"additional","affiliation":[{"name":"The Emmes Company, Inc, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Linton","sequence":"additional","affiliation":[{"name":"Usona Institute, Fitchburg, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[{"name":"NYU Langone Center for Psychedelic Medicine, Department of Psychiatry, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"joi230092r1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.4088\/JCP.10m06223blu","article-title":"The future of psychopharmacology of depression.","volume":"71","author":"Chang","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"joi230092r2","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1017\/S1461145711000083","article-title":"A critical review of pharmacotherapy for major depressive disorder.","volume":"14","author":"Dupuy","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"joi230092r3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1017\/S0033291721004943","article-title":"Clinical research challenges posed by difficult-to-treat depression.","volume":"52","author":"Rush","year":"2022","journal-title":"Psychol Med"},{"issue":"4","key":"joi230092r4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265928","article-title":"Antidepressants and health-related quality of life (HRQoL) for patients with depression: analysis of the medical expenditure panel survey from the United States.","volume":"17","author":"Almohammed","year":"2022","journal-title":"PLoS One"},{"issue":"12","key":"joi230092r5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database.","volume":"45","author":"Gastaldon","year":"2022","journal-title":"Drug Saf"},{"issue":"12","key":"joi230092r6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial.","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"2","key":"joi230092r7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"12","key":"joi230092r8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"7","key":"joi230092r9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"joi230092r10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"joi230092r11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial.","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"joi230092r12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up.","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"15","key":"joi230092r13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression.","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"joi230092r14","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression.","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"joi230092r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial.","volume":"56","author":"von Rotz","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"14","key":"joi230092r16","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1017\/S0033291722003191","article-title":"Is good science leading the way in the therapeutic use of psychedelic drugs?","volume":"52","author":"Hall","year":"2022","journal-title":"Psychol Med"},{"issue":"10","key":"joi230092r17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review.","volume":"36","author":"Breeksema","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"10","key":"joi230092r18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the bursting of the psychedelic hype bubble.","volume":"79","author":"Yaden","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"joi230092r19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"joi230092r22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"joi230092r23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety.","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"joi230092r24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"3","key":"joi230092r25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/acps.v143.3","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression.","volume":"143","author":"Turkoz","year":"2021","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"joi230092r26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","article-title":"Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression.","volume":"27","author":"Hengartner","year":"2022","journal-title":"BMJ Evid Based Med"},{"issue":"11","key":"joi230092r27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/da.v25:11","article-title":"Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone.","volume":"25","author":"Kobak","year":"2008","journal-title":"Depress Anxiety"},{"key":"joi230092r28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1744-859X-5-3","article-title":"Administering the MADRS by telephone or face-to-face: a validity study.","volume":"5","author":"Hermens","year":"2006","journal-title":"Ann Gen Psychiatry"},{"key":"joi230092r29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability.","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"joi230092r31","first-page":"75","article-title":"Emotional blunting, cognitive impairment, bone fractures, and bleeding as possible side effects of long-term use of SSRIs.","volume":"16","author":"Marazziti","year":"2019","journal-title":"Clin Neuropsychiatry"},{"issue":"5","key":"joi230092r32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying harms is key to improving psychedelic-assisted therapy: participants call for changes to research landscape.","volume":"80","author":"McNamee","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"joi230092r33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"joi230092r34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis.","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"joi230092r35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.","volume":"18","author":"Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"1","key":"joi230092r36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1556\/2054.2019.016","article-title":"Culturally informed research design issues in a study of MDMA-assisted psychotherapy for posttraumatic stress disorder.","volume":"4","author":"Williams","year":"2019","journal-title":"J Psychedelic Stud"},{"key":"joi230092r20","volume-title":"The Structured Clinical Interview for DSM-5 Disorders: Clinical Version","author":"First","year":"2015"},{"key":"joi230092r21","unstructured":"Collection of race and ethnicity data in clinical trials: guidance for industry and Food and Drug Administration Staff. US Food and Drug Administration. Updated September 14, 2018. Accessed May 24, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials"},{"key":"joi230092r30","unstructured":"CFR - Code of Federal Regulations Title 21. 2023. Accessed March 24, 2023; https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2808950\/jama_raison_2023_oi_230092_1706031522.91308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T11:00:35Z","timestamp":1706266835000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2808950"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.14530","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}